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Abstract. 
The activating natural cytotoxicity receptor NKp30 is critical for natural killer (NK) cell 
function and tumor immune surveillance. The natural cytotoxicity receptor-3 (NCR3) gene is 
transcribed into several splice variants whose physiological relevance is still incompletely 
understood. In this study, we investigated the role of NKp30 and its major ligand B7 
homolog 6 (B7-H6) in patients with hepatocellular carcinoma (HCC). Peripheral blood NK 
cell phenotype was skewed toward a defective/exhausted immune profile with decreased 
frequencies of cells expressing NKp30 and natural killer group 2 member d (NKG2D) and an 
increased proportion of cells expressing T-cell immunoglobulin and mucin-domain 
containing-3 (Tim-3). Moreover, NKp30-positive NK cells had a reduced expression of 
NCR3 immunostimulatory splice variants, and an increased expression of the inhibitory 
variant in patients with advanced tumor, resulting in deficient NKp30-mediated functionality. 
Tumor-infiltrating lymphocytes showed a prevalent inhibitory NKp30 isoform profile, 
consistent with decreased NKp30-mediated function. Of note, there were significant 
differences in the cytokine milieu between the neoplastic and the surrounding non-neoplastic 
tissue which may have further influenced NKp30 function. Exposure of NK cells to B7-H6 
expressing HCC cells significantly down-modulated NKp30, that was prevented by siRNA-
mediated knockdown, suggesting a role for this ligand in inhibiting NKp30-mediated 
responses. Interestingly, B7-H6 expression was reduced in HCC tissue and simultaneously 
augmented as a soluble form in HCC patients’, particularly those with advanced staging or 
larger nodule size. Conclusions: these findings provide evidence in support of a role of 
NKp30 and its major ligand in HCC development and evolution. 
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Introduction. 
Natural killer (NK) cells play a significant role in innate immune responses to cancer cells via 
recognition of germline-encoded ligands of positive and negative signaling receptors. Lysis 
of tumor targets occurs through reduction of inhibitory signals and a simultaneous increase in 
activating signals that are necessary for NK cell triggering 
(1-3)
. Activating receptors include 
DNAM-1, NKG2D, and the natural cytotoxicity receptors (NCR), whose ligands comprise 
both MHC-like and non-MHC molecules. The NCR family includes NKp30 (NCR3), NKp44 
(NCR2) and NKp46 (NCR1) which are type I transmembrane glycoproteins comprising one 
(NKp30 and NKp44) or two (NKp46) Ig-like extracellular domains 
(4)
. The NCR3 gene is 
transcribed into three major isoforms (NKP30a, NKp30b and NKp30c) of the NKp30 protein 
that are generated by alternative splicing and that have different biological functions. The 
NKp30a and NKp30b isoforms are considered immunostimulatory as they induce 
cytotoxicity and Th1 cytokine secretion, respectively, while the NKp30c isoform shows an 
immunosuppressive activity triggering IL-10 release. Furthermore, the relative abundance of 
the mRNA encoding the NKp30c isoform compared to isoform a or b can negatively impact 
on the prognosis and evolution of different malignancies and might be associated with 
advanced liver disease in HCV-infected patients 
(5-8)
. Moreover, the expression of different 
NCR3 splice variants by NK cells delineates functionally distinct subsets and is governed by 
the cytokine-defined microenvironment 
(9,10)
. The NKp30 receptor recognizes the HLA–B-
associated transcript 3 (BAT3), the human cytomegalovirus pp65 tegument protein and the 
cell surface protein B7 homolog 6 (B7-H6), a member of the B7 family of receptors 
(11-13)
. 
Interestingly, B7-H6 is not expressed by normal human tissues but is selectively expressed on 
stressed cells, including both solid and transformed blood cells, which can up-regulate B7-H6 
expression and enhance tumor susceptibility to NK cell lysis 
(14-16)
. The interaction of B7-H6 
on tumor cells with NKp30 on NK cells results in interferon-γ (IFN-) production and tumor 
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cell killing, suggesting that the NKp30–B7-H6 axis can be exploited for cancer 
immunotherapy 
(17)
. In addition, B7-H6 can also be induced as a stress protein by viral 
infections closely linked to carcinogenesis such as hepatitis B virus (HBV) 
(18)
. Current 
evidence indicates that malignant cells can also bypass the NK surveillance by releasing B7-
H6 as soluble proteins that block NKp30 activity, suggesting that this may be an immune 
escape mechanism of tumor cells from NK cell-mediated killing 
(19)
. It is clear from the 
aforementioned that the NKp30-B7H6 axis represent an important pathway in chronic 
inflammation proceeding to tumor development. One such example is hepatocellular 
carcinoma (HCC) which may develop in the setting of advanced chronic hepatitis B (HBV) 
and chronic hepatitis C (HCV) virus infections 
(20)
.  
In this study we have investigated the NKp30-B7-H6 axis in patients with HCC. We showed 
that peripheral and tumor-infiltrating NKp30+ NK cells have deficient NKp30-mediated 
functionality and altered expression of NCR3 splice variants. Moreover, B7-H6 expression 
was reduced in HCC tissue and simultaneously augmented as a soluble form in the serum of 
HCC patients, particularly those with advanced staging or larger nodule size. These findings 
provide evidence in support of a role of NKp30 and its major ligand in HCC development 
and evolution. 
 
Materials and Methods. 
Complete technical details are reported in Supplementary Materials and Methods. Briefly, 
paired blood and tissue infiltrating lymphocytes were obtained from patients undergoing 
surgical liver resections for HCC (Supplementary Table 1) and prepared for phenotype 
determination and redirected functional analysis via NKp30 ligation, RNA extraction and 
qPCR to detect NKp30 isoforms. Primary HCC cell cultures were established as described in 
Supplementary M&M. Liver samples from HCC and cirrhotic patients were retrospectively 
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examined as described in Supplementary M&M. NKp30 down-regulation experiments using 
B7-H6 expressing cells and B7-H6 siRNA knock-down are also described in Supplementary 
M&M. 
Statistical analysis was performed using the GraphPad Prism 6 software. The non-parametric 
Wilcoxon matched-pairs signed rank test or Mann-Whitney U test as well as parametric 
paired or unpaired t test were used as appropriate. The Dunn’s multiple comparison test was 
used to compare more than two groups of data. Pearson test was used to examine 
correlations. A p value ≤0.05 was deemed statistically significant. 
 
Results. 
Peripheral NK cells show an exhausted phenotype in HCC patients and NKp30-
expressing NK cells are enriched in tumor-infiltrating lymphocytes. 
We investigated the frequency of circulating NK cells in HCC patients and HC, according to 
the gating strategy shown in Supplementary fig. 1, and found that frequencies of total 
peripheral NK cells and of the CD56
bright 
 and CD56
dim 
subsets (Fig. 1A) were comparable in 
HCC patients and HC. The frequency of peripheral NK cells carrying NKp30 receptor and its 
expression were instead significantly lower in patients with HCC compared to HC (Fig. 1B-
C). There were no differences in NKp30 expression according to liver disease etiology (not 
shown). The frequency of the immunomodulatory T-cell immunoglobulin- and mucin-
domain-containing molecule-3 (Tim-3) receptor was significantly higher in HCC patients’ 
NK cells, compared to HC NK cells (Fig. 1D). Moreover, there was a statistically significant 
reduction in the proportion of NKG2D+ (Fig. 1E) and a significant increase in the proportion 
of CD69+ (Fig. 1F) NK cells from patients with HCC compared with controls. At the same 
time, no statistically significant differences were noted in the proportion of  programmed 
death receptor 1 (PD-1), NKG2A, Fas ligand (FasL), T cell immunoreceptor with Ig and 
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ITIM domains (TIGIT)  and  NKp46 (Supplementary Fig 2A-E) expressing NK cells 
compared to HC. We further investigated intrahepatic NK cell receptors in HCC patients and 
found a lower frequency of total NK cells in TIL compared to LIL (Fig. 2A), as shown by 
others 
(21, 22)
. However, the proportion of NKp30+ NK cells and the mean fluorescence 
intensity (MFI) of the NKp30 receptor were significantly higher in TIL- compared with LIL-
NK cells (Fig. 2B-D). There was a higher frequency of NKp30+ NK cells in the CD56
bright 
 
subset in TIL compared with LIL (Fig. 2E). In contrast, the proportion of NKp46+ NK cells 
and the NKp46 MFI were similar in tumor and non-tumor NK cells (data not shown).  
 
Deficient NKp30-mediated functionality and altered NKp30 isoform profile in HCC 
patients.  
Altered expression of NKp30 receptor in HCC patients prompted us to study the NKp30-
mediated cytolytic potential and cytokine production of peripheral and intrahepatic NK cells 
of HCC patients, using an ex vivo redirected functional (ADCC) assay. PBMC, TIL and 
matched LIL were incubated overnight with or without IL15 and subsequently co-cultured 
with the FcR+ P815 murine cell line in the presence of anti-NKp30 mAb. Patients with 
chronic HCV infection without HCC were added as disease controls. There was no difference 
in peripheral NKp30-mediated cytotoxicity between patients with HCC, patients with chronic 
HCV infection and HC (Fig. 3A). NKp30 expression was reduced in the HCV+ disease 
control group (not shown) compared to HC, in keeping with previously published data from 
our laboratory 
(8)
. After IL15 stimulation, NKp30-mediated cytotoxicity was significantly 
augmented in HCV+ patients compared to HC, whereas HCC patients displayed a lower 
cytotoxic potential compared to HCV+ patients (Fig. 3A). NKp30-mediated IFN-γ 
production was significantly reduced in peripheral blood NK cells from both HCC and HCV+ 
patients compared to HC, which was maintained in HCC patients also after IL15 stimulation 
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(Fig. 3B). There was a trend toward a more profound reduction in IFN secretion for HCC 
patients compared to non-HCC, HCV+ controls (Fig. 3B). The NKp30-mediated functional 
dichotomy exhibited by peripheral blood NK cells in chronic HCV infection, i.e. increased 
degranulation and poor cytokine production, is consistent with previous findings from our 
own and other laboratories 
(23, 24)
. 
When we analyzed the intrahepatic compartment, we found that the NKp30-mediated 
degranulation ability of TIL-NK cells tested by reverse ADCC was significantly reduced 
compared with matched LIL-NK cells (Fig. 3C). IL15 stimulation was unable to rescue 
NKp30-mediated degranulation in TIL-NK cells, despite being able to boost NKp30 
expression (data not shown). No statistically significant differences in IFN-γ (and TNFα, not 
shown) production were noted following NKp30 ligation (Fig. 3D).  
Recent studies have shown that the NKp30 isoform expression pattern affects the NK cell 
functionality, the prognosis and evolution in the settings of cancer and infection 
(6-8)
. We 
investigated whether alternatively spliced variants of the NCR3 gene might explain the 
reduced NKp30-mediated cytokine production of peripheral blood NK cells in HCC patients. 
To this end, we quantified the three major NKp30 isoforms (NKp30a, b and c) in freshly 
isolated PBMC of patients and HC using qPCR. The relative expression of the 
immunostimulatory NKp30a and NKp30b isoforms was significantly lower in HCC patients 
than in HC (Fig. 4A). In agreement with the low NKp30a and b transcripts, the ac and bc 
ratio values were lower in NK cells from patients with HCC compared to HC (Fig. 4B). 
Interestingly, when HCC patients were analyzed according to the Barcelona Clinic for Liver 
Cancer (BCLC) staging classification, we found that the immunosuppressive NKp30c 
isoform was increased in patients with advanced tumor (Fig. 4C). Notably, there was a 
statistically significant positive correlation between the NKp30 a/c isoform ratio and IFN by 
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NK cells, providing further evidence in support of the immunostimulatory function of the 
NKp30a isoform (Fig. 4D).  
In consideration of the inhibitory function of NKp30 
(25)
 and the potential role of 
microenvironment cytokines in influencing the NCR3 splice variants 
(9)
, we explored whether 
a switched NKp30 isoform profile could explain the deficient degranulation efficiency of 
TIL-NK cells in HCC patients. To this end, we quantified the three major NKp30 isoforms in 
freshly isolated LIL and matched TIL-NK cells. As shown in fig. 4E, the relative expression 
of the immunostimulatory NKp30b isoforms was significantly lower in TIL-NK cells than in 
LIL-NK cells. TIL-NK cells exhibited a reduced bc ratio compared to the matched non-
tumor liver counterpart, suggesting a prevalent inhibitory NKp30-mediated signaling (Fig. 
4F). This difference in tissue-specific NKp30 isoform profile and NK cell functionality 
prompted us to examine changes in the cytokine content in the neoplastic and the surrounding 
non-neoplastic liver tissue. To this end, we analyzed mRNAs of selected cytokines that were 
previously shown to be involved in the necroinflammatory process leading to advanced 
fibrosis and liver carcinogenesis 
(26-31)
, as well as in NK cell regulation 
(32)
. There was a 
reduced mRNA content of certain cytokines, including IL-6, IL-8 and IL-10, in the tumor 
compared with the non-neoplastic tissue, whereas no statistically significant differences were 
observed for IL-18 and TGF- mRNAs (Fig. 5).  
 
NKp30 receptor is downregulated after exposure to B7-H6 expressing HCC cells.   
To assess whether NKp30 expression could be influenced by B7-H6 contact we performed 
co-culture experiments with hepatocellular carcinoma Huh7.5 cell line expressing the B7-H6 
ligand. As shown in fig. 6A, B7-H6 expression was higher on HCV-infected Huh7.5 cells 
than on uninfected cells. The frequency of NK cells carrying the NKp30 receptor and its 
expression were downregulated after exposure of PBMC from HC to uninfected Huh7.5 cells, 
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expressing low levels of B7-H6. A stronger downregulation was shown when PBMC were 
incubated with HCV-infected Huh7.5 cells, expressing higher levels of B7-H6, both as 
percentage and MFI (Fig. 6B-C). In contrast, NKp46 expression remained unchanged (data 
not shown). Representative dot plots showing NKp30+ and NKp46+ NK cell frequencies 
after B7-H6 exposure are shown in supplementary 3.  B7-H6-induced NKp30 downregulation 
was also confirmed by siRNA-mediated knockdown. Surface B7-H6 expression was 
evaluated on HepG2 cells after transfection with B7-H6- and or negative control-siRNA by 
flow cytometry and qPCR (Fig. 6D and Fig. 4S). As shown in fig. 6D, siRNA-mediated 
knockdown of B7-H6 was able to reduce B7-H6 expression in HepG2 cells. The frequency of 
NK cells carrying the NKp30 receptor and its expression were higher after exposure of 
PBMC from HC to siRNA-B7-H6-transfected HepG2 cells compared to siRNA-negative 
control (Fig. 6E-F). B7-H6-induced NKp30 downregulation was also confirmed after PBMC 
exposure to the breast carcinoma cell lines MCF-7/VC or MCF-7/B7-H6, retrovirally 
transduced with pMXneo or pMXneo-CD8L-Myc tag-B7-H6, respectively (Fig. 5S).  
Furthermore, to assess whether NKp30 expression could be influenced by soluble B7-H6 
(sB7-H6) we performed experiments incubating PBMC from HC with heterologous HC’s 
serum and HCC patients’ serum. No statistically significant differences were observed, 
suggesting that NKp30 down-regulation requires B7-H6 to be cell-associated (Supplementary 
Fig. 6).  
 
B7-H6 protein expression is reduced in tumor tissue of HCC patients.   
Expression of the NKp30 ligand B7-H6 was evaluated in HCC biopsy specimens by 
immunohistochemistry and compared to cirrhotic livers. B7-H6 was highly expressed in 
cirrhotic livers and was significantly less expressed in HCC tissue stratified according to the 
degree of differentiation: well-, moderately- and poorly-differentiated tissue (Fig. 7A). 
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Interestingly, we found that poorly-differentiated tumor cells showed a trend toward lower 
B7-H6 expression compared to better differentiated HCC tissues. Immunohistochemical 
staining showed that B7-H6 was mainly localized in the cytoplasm and on the membrane of 
hepatocytes as shown in fig. 7B. To investigate whether different levels of B7-H6 protein 
expression by immunohistochemistry in situ were caused by a decrease in gene transcription, 
we analysed B7-H6 mRNA levels in HCC tissues along with matched non-tumor specimens 
but we were unable to detect significant differences (Fig. 7C), suggesting that decreased B7-
H6 protein expression did not result from reduced transcript levels, and might have occurred 
via other post-transcriptional mechanisms. Schlecker et al. demonstrated a novel mechanism 
of immune escape in which tumor cells impede NK cell recognition by metzincin-mediated 
shedding of B7-H6 
(33)
. To address whether this mechanism plays a role in B7-H6 
downregulation on HCC patients we treated HCC primary cell lines with different ADAM-
specific inhibitors. B7-H6 surface expression was measured by flow cytometry on untreated 
HCC primary cell lines or after exposure to ADAM-10 and ADAM-17 inhibitors LT4 or 
MN8 or to solvent alone (DMSO) for 24 h. As shown in Supplementary fig. 7, there was a 
modest and not always consistent increase in B7-H6 surface expression only after exposure 
of HCC cells to MN8. 
 
Soluble B7-H6 serum concentrations are elevated in HCC patients with intermediate 
and advanced tumors and correlate with clinical parameters. 
Based on in situ expression of B7-H6 in HCC, we next investigated whether sB7-H6 was 
detectable in patients’ sera by ELISA. As shown in fig. 8A, higher serum B7-H6 levels were 
detected in HCC patients with intermediate and advanced tumor, classified according to the 
BCLC staging classification, compared to early stage tumors (BCLC-A) and to HC and 
cirrhotic patients. Differences between HC, cirrhosis and HCC remained highly significant 
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when HCC were not stratified according to BCLC stage (not shown). There were no 
significant differences in sB7-H6 levels when HCC patients were stratified according to 
etiology or tumor grading (data not shown). Moreover, there were positive correlations 
between sB7-H6 levels and HCC nodule size and serum alpha fetoprotein values (Fig. 8B and 
C). 
 
Discussion. 
Functional deficiencies of circulating and intrahepatic NK cells have been demonstrated in 
various human cancers including hepatocellular carcinoma 
(21, 22, 25, 34, 35)
. Nevertheless, the 
mechanisms responsible for altered NK cell effector function and their association with 
disease progression remain largely unexplored. Previous studies found a reduction in the 
proportion of peripheral blood NK cells and of CD56
dim 
phenotype in HCC patients 
(21, 22, 35)
 
which could contribute to reduced immune surveillance, whereas no differences were found 
in our study between patients and controls. These discrepancies might be a consequence of 
patient selection, since our patients had an overall more advanced disease, a larger proportion 
of them being categorized as BCLC-B, C, D, whereas the vast majority of patients in Cheung 
et al.
(22)
 and Cariani et al.
(35) 
 were classified as BCLC-A. An altered NK cell phenotype may 
reflect NK cell anergy which, however, does not always correlate with altered expression of 
activating and inhibitory receptors on NK cells in HCC patients. Relevant to this statement, 
there are controversial data regarding the frequencies of NK cells carrying NKG2D and 
NKG2A receptors in circulating and intrahepatic NK cells 
(21, 22, 35)
. Interestingly, phenotypic 
analysis of our patients with HCC showed decreased frequencies of NK cells expressing 
NKp30 and NKG2D activating receptors, together with an increased frequency of Tim-3, 
suggesting that innate immunity is skewed toward exhausted anti-tumor immune responses 
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despite of an increased proportion of NK cells expressing the CD69 early activation marker. 
Recent studies have reported conflicting data about Tim-3 function in NK cells 
(36-38)
. 
Ndhlovu and colleagues showed that Tim-3 inhibits NK cell–mediated cytotoxicity (36), 
whereas another study suggested that Tim-3 may instead enhance IFN-γ production (37). Both 
studies focused on healthy donors and not patients with chronic diseases, such as cancer. In 
cancer patients, da Silva and colleagues showed that Tim-3 could function as an NK-cell 
exhaustion marker in advanced melanoma and that its blockade reverses the NK exhausted 
phenotype 
(38)
. Functional NK cell deficiency might be also associated with an increased 
regulatory T cell frequency, an altered dendritic cell function and an increased proportion of 
myeloid-derived suppressor cells 
(21, 25, 39)
. Apart from those mechanisms, alternative splicing 
of the NCR3 gene has been shown to profoundly influence NKp30-dependent function and it 
has been correlated with the prognosis and evolution in gastrointestinal stromal tumor 
patients, as well as other cancers, viral infections and miscarriage 
(5-10)
. However, no 
information is currently available on NCR3 splice variant profile and function in liver cancer. 
In the present study we showed that in HCC patients NK cells displayed reduced NKp30 
expression, as well as NKp30-mediated cytokine secretion and cytotoxicity. We also showed, 
for the first time, that peripheral and tumor infiltrating NKp30-expressing NK cells displayed 
altered expression of the major NKp30 isoforms (NKp30a, NKp30b and NKp30c), which is 
compatible with defective NKp30-mediated tumor immune surveillance in HCC patients. 
Indeed, PBMC of HCC patients displayed a lower mRNA expression level of the NKp30a 
and b immunostimulatory isoforms compared to HC and in those patients with advanced 
tumor, expression of the inhibitory NKp30c isoform was clearly increased. Furthermore, NK 
cells displaying a reduced NKp30 a/c isoform ratio exhibited a reduced NKp30-mediated 
cytokine production. Moreover, considering the relative expression of the different NCR3 
alternative splice variants, there was a bias toward a prevalent inhibitory NKp30 isoform 
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profile in the liver compartment, consistent with decreased NKp30-mediated function. The 
aforementioned shed new light on the role for the NKp30 receptor in HCC surveillance. In 
line with this interpretation, NKp30-mediated cytokine production by circulating NK cells 
was found to be reduced in HCC patients compared with controls, in keeping with a lower 
frequency of NKp30+ NK cells and a lower density of NKp30 receptor expression in HCC 
compared with HC. These findings somehow differ from those obtained in the intrahepatic 
compartment in which NKp30-mediated NK cell degranulation was reduced despite higher 
relative frequency of NKp30+ cells and higher density of the NKp30 receptor in neoplastic 
compared with non-neoplastic adjacent tissues. In this respect, NKp30-mediated responses 
may be influenced by differences in the cytokine milieu between the neoplastic and non-
neoplastic tissue, as shown in previous studies supporting an epigenetic role for certain 
cytokines, such as TGF-, IL-15 and IL-18, that are enriched in a specific microenvironment, 
to convert the NCR3 splice variant profile of NK cells and to affect the NK cytolytic behavior 
(9, 10)
. In line with these findings, our data showing a reduced pro-inflammatory cytokine (IL-
6, IL-8) mRNA content and a concomitant inhibitory signal delivered by unaltered TGF- 
mRNA expression in the neoplastic tissue, support the existence of an inhibitory 
microenvironment affecting NK cell responses. Thus, the evidence gathered in this study 
pointed to peculiar characteristics of the neoplastic tissue in patients with HCC, in whom the 
NKp30 isoform analysis was compatible with an inhibitory profile, despite an increased 
relative proportion of NKp30 positive NK cells.  
Our data clearly emphasized the role of B7-H6 in regulating NKp30 expression. Interaction 
of B7-H6 with NKp30 on NK cells leads to efficient NK cell activation and target cell killing 
(40)
. The absence of B7-H6 transcripts in normal tissues and the presence in tumor cells, on 
inflammatory monocytes during sepsis and in viral infections, define B7-H6 as an example of 
a stress-induced self molecule 
(18, 41, 42)
. Until now, hepatic B7-H6 expression remained 
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poorly explored. Zou et al. investigated B7-H6 protein expression on HBV-induced acute on 
chronic liver failure and another study showed B7-H6 expression at the transcriptional level 
in hepatocellular carcinoma 
(18, 43)
; however, the non-neoplastic liver was only poorly 
explored. In the former study, B7-H6 expression, assessed by immunohistochemistry, was 
found to be markedly enhanced on HBV-infected hepatocytes compared to the healthy liver 
and its expression positively correlated with the severity of liver injury in this clinical setting 
(18)
. In addition, Fiegler et al. observed elevated B7-H6 mRNA levels in HCC tissue 
compared to normal liver controls 
(43)
. Importantly, our results compared tumor tissue and 
cirrhotic liver showing a significantly reduced B7-H6 expression in HCC tissue by 
immunohistochemistry. Notably, the HCC tissue exhibited different intensity of B7-H6 
expression according to tumor differentiation status, the ligand being less expressed, though 
not significantly so, in poorly differentiated HCC. Decreased B7-H6 expression was not 
caused by altered gene transcription, since tumor B7-H6 mRNA levels were not significantly 
different from those of the surrounding non-neoplastic tissue, suggesting that other 
mechanisms might be involved. Similarly to other members of the B7 family, B7-H6 was 
also identified in a soluble form capable of binding to NKp30 receptor and to prevent 
NKp30-mediated NK cell triggering. Release of sB7-H6 was shown to be at least in part 
compatible with a metzincin-mediated shedding mechanism, since ADAM-specific inhibitors 
slightly increased B7-H6 surface expression on primary HCC cell lines, in agreement with 
data in melanoma patients 
(33)
. The role of soluble B7-H6 in HCC is not entirely clear, since a 
short incubation with heterologous serum containing cell-free B7-H6 was unable to decrease 
the proportion of NKp30+ NK cells in vitro, whereas cell-associated B7-H6 clearly was. 
Instead, a competing role for B7-H6 has convincingly been shown in ovarian carcinoma in 
which down-modulation of the NKp30 receptor expression and function on tumor-associated 
NK cells were associated with the presence of its ligand B7-H6 as a surface/cytosolic 
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molecule in tumor cells as well as a soluble molecule 
(19)
. In line with this observation, and in 
agreement with our data showing a clear ligand-induced receptor down-modulation, higher 
NKp30 expression observed in TIL compared to LIL may be due to an absent down-
regulatory effect caused by reduced ligand-receptor interaction. Evidence in support of this 
hypothesis comes from our data showing decreased expression of B7-H6 ligand in HCC 
tissues. Moreover, significantly elevated levels of sB7-H6 were detected in sera of HCC 
patients with intermediate and advanced tumor compared with healthy controls and cirrhotic 
patients, suggesting a potential inhibitory role for this soluble ligand on NKp30 expression 
and NKp30-mediated NK cell activity. Our data suggesting that B7-H6 is released by 
sheddases from neoplastic cells are compatible with larger amounts of soluble ligand being 
shed from larger neoplastic nodules or advanced HCC. This may represent an evasion 
mechanism from the host immune surveillance. 
In conclusion, our study provides evidence in support of an alteration of the NKp30/B7-H6 
axis in HCC and reveals several mechanisms that can be exploited for novel 
immunotherapeutic approaches for liver cancer. It may be envisaged that beyond restoring 
cytotoxic T lymphocyte activity with checkpoint inhibitors, such as PD-1/PD-L1-specific 
monoclonal antibodies 
(44)
, it could also be possible to associate specific immune 
interventions to modulate altered NK cell activity. Also, it is of interest that sorafenib, which 
for years was the only systemic treatment available for patients with advanced HCC 
(45)
, 
primes proinflammatory responses of macrophages located within the HCC 
microenvironment and induces anti-tumor NK cell responses in a cytokine-dependent 
fashion, providing new insights for immune stimulatory treatments 
(46)
.  
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Legends. 
Figure 1. Peripheral NK cells of HCC patients show an exhausted phenotype in HCC 
patients and NKp30-expressing NK cells are enriched in tumor-infiltrating 
lymphocytes. Frequencies of circulating NK cells, CD56
bright 
and CD56
dim
 subsets (A), 
NKp30+ NK cells and NKp30-MFI (B-C) in HCC patients (n=55) and HC (n=39). 
Frequencies of circulating Tim-3 (D), NKG2D (E) and CD69 (F) expressing NK cells in 
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HCC patients (n=14, n=47 and  n=44, respectively) and HC (n=10, n=38 and n=34, 
respectively). Middle bars represent median values, box plots are 25% and 75% percentiles, 
whiskers are minimum and maximum values. The Mann-Whitney U test or the unpaired t test 
were used to compare data. 
 
Figure 2. Increased proportion of NKp30 receptor-positive NK cells and NKp30 density 
in TIL-NK cells of HCC patients. The frequency of total NK cells in TIL (n=23) was lower 
compared with matched LIL (A), with a relative increase of NKp30+ NK cells (B) and 
NKp30 receptor density (C). (D), Representative dot plots showing the frequencies of 
NKp30-positive NK cells in LIL and matched TIL. (E), Frequency of NKp30-expressing LIL 
and TIL-NK cells within the CD56
bright 
and CD56
dim 
subsets (n=18). Middle bars represent 
median values, box plots are 25% and 75% percentiles, whiskers are minimum and maximum 
values. The Wilcoxon matched-pairs signed rank test or paired t test were used to compare 
data. 
 
Figure 3. Deficient NKp30-mediated function in HCC patients. (A), NKp30-mediated 
degranulation in unstimulated or IL15-stimulated PBMC of HCC patients (n=30), HC (n=29) 
and HCV+ patients (n=11). (B), NKp30-mediated cytokine production in unstimulated or 
IL15-stimulated PBMC of HCC patients (n=11), HC (n=15) and HCV+ patients (n=11). 
NKp30-mediated degranulation (C) and NKp30-mediated cytokine production (D) in 
unstimulated or IL15-stimulated LIL and matched TIL-NK cells (n=13). Middle bars 
represent median values, box plots are 25% and 75% percentiles, whiskers are minimum and 
maximum values. The Mann-Whitney U test, unpaired t test or the Wilcoxon matched-pairs 
signed rank test were used to compare data. 
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Figure 4. Altered NKp30 isoform balance in HCC patients. Relative expression of NKp30 
isoforms (A) and NKp30 ac, bc and ab ratios (B) in PBMC of 15 HC and 33 HCC 
patients. (C), NKp30c isoform expression in HCC patients with stratified according to BCLC 
staging classification. (D), The Pearson correlation coefficient was used to examine 
dependence between NKp30 a/c isoform ratio and NKp30-mediated IFNγ production upon 
IL-15 stimulation, in 19 HCC patients. The relative expression of NKp30 isoforms (E) and 
the NKp30 ac, bc and ab ratios (F) were determined in LIL and matched TIL-NK cells 
from 19 HCC patients.  
 
Figure 5. Cytokine profile in HCC and non-neoplastic tissue. IL-6, IL-8, IL-10, IL-18 and 
TGF- mRNA expression on HCC tissues compared with matched non-neoplastic 
surrounding tissue (n=11). The Wilcoxon matched-pairs signed rank test was used for 
comparison. 
 
Figure 6. NKp30 is down-regulated after co-culture with a B7-H6 positive HCC cell line. 
(A), B7-H6 expression on uninfected or HCV-infected Huh7.5 cell line. (B), Frequency of 
NKp30+ NK cells (B) and NKp30 MFI (C) in HC PBMC (n=11) cultured alone or co-
cultured with uninfected or HCV-infected Huh7.5 cell line. (D), B7-H6 expression on HepG2 
cells transfected with B7-H6- and or control-siRNA. The frequency NKp30+ cells (E) and 
NKp30 expression (F) after exposure of PBMC from 10 HC to siRNA-B7-H6-transfected 
HepG2 cells, siRNA control-transfected HepG2 cells and medium alone. The paired t test 
was used to compare data. 
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Figure 7. B7-H6 protein expression is reduced on neoplastic tissue in HCC patients. (A), 
Immunohistochemical analysis of B7-H6 protein expression on HCC tissue stratified 
according to degree of differentiation compared to cirrhotic livers (n=28). Data are presented 
as mean values ± SEM. The Dunn's Multiple Comparison test was used to compare data, 
***P<0.001. WD-HCC= well differentiated HCC (n=18), MD-HCC= moderately 
differentiated HCC (n=34), PD-HCC= poorly differentiated HCC (n=5). (B), Representative 
B7-H6 and matched negative control or haematoxylin-eosin immunohistochemistry staining 
on cirrhotic samples and HCC tissue classified as WD-, MD- and PD-HCC (100x 
magnification). (C), mRNA B7-H6 expression on HCC tissues along with matched non-
neoplastic specimens (n=11). The Wilcoxon matched-pairs signed rank test was used. Not 
statistically significant (ns). 
 
Figure 8. Soluble B7-H6 protein correlates with clinical parameters and is higher in 
patients with BCLC stage B. (A), Serum B7-H6 concentrations in HCC patients stratified 
according to BCLC stage (n=87), cirrhotic patients (n=39 ) and HC (n=48). Data are 
presented as mean values ± SEM. The Dunn's Multiple Comparison test was used to compare 
data, *P<0.05,  ***P<0.001. The Pearson correlation coefficient was used to examine 
dependence between sB7-H6 protein (B) and maximum nodule size or sAFP (C), in HCC 
patients.   
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